 | This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023) |
ARO-APOC3 is an apolipoprotein C-III antagonist and RNAi therapeutic investigated for dyslipidemia and familial chylomicronemia syndrome.
References
- Hegele, Robert A (November 2022). "APOC3 Interference for Familial Chylomicronaemia Syndrome". TouchREVIEWS in Endocrinology. 18 (2): 82–83. doi:10.17925/EE.2022.18.2.82. ISSN 2752-5457. PMC 9835816. PMID 36694895.
- Clifton, Peter; Sullivan, David; Baker, John; Schwabe, Christian; Thackwray, Susan; Scott, Russell; Hamilton, James; Lira Pineda, Armando J; Given, Bruce; Melquist, Stacey; Chen, Iris; San Martin, Javier; Watts, Gerald F; Goldberg, Ira J; Knowles, Josh; Gaudet, Daniel; Hegele, Robert A; Ballantyne, Christie M (16 November 2021). "Abstract 10357: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia". Circulation. 144 (Suppl_1). doi:10.1161/circ.144.suppl_1.10357. S2CID 247578996.